메뉴 건너뛰기




Volumn 24, Issue 5, 2014, Pages 829-837

Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells

Author keywords

Irinotecan; Isobologram; Ovarian clear cell carcinoma; Topotecan; Trabectedin

Indexed keywords

CISPLATIN; DOXORUBICIN; EVEROLIMUS; FIRTECAN; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; TOPOTECAN; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; RAPAMYCIN; TETRAHYDROISOQUINOLINE DERIVATIVE;

EID: 84904094783     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000143     Document Type: Article
Times cited : (12)

References (30)
  • 1
    • 34548491626 scopus 로고    scopus 로고
    • Prognostic factors for stage iii epithelial ovarian cancer: A gynecologic oncology group study
    • Winter WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621-3627.
    • (2007) J Clin Oncol. , vol.25 , pp. 3621-3627
    • Winter, W.E.1    Maxwell, G.L.2    Tian, C.3
  • 2
    • 0034213974 scopus 로고    scopus 로고
    • Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy
    • Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584-2589.
    • (2000) Cancer. , vol.88 , pp. 2584-2589
    • Sugiyama, T.1    Kamura, T.2    Kigawa, J.3
  • 3
    • 77949396071 scopus 로고    scopus 로고
    • Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy
    • Bamias A, Psaltopoulou T, Sotiropoulou M, et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010;116: 1462-1468.
    • (2010) Cancer. , vol.116 , pp. 1462-1468
    • Bamias, A.1    Psaltopoulou, T.2    Sotiropoulou, M.3
  • 4
    • 34247156633 scopus 로고    scopus 로고
    • Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary
    • Crotzer DR, Sun CC, Coleman RL et al. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007;105:404-408.
    • (2007) Gynecol Oncol. , vol.105 , pp. 404-408
    • Crotzer, D.R.1    Sun, C.C.2    Coleman, R.L.3
  • 5
    • 77249088752 scopus 로고    scopus 로고
    • Trabectedin: A review of its use in soft tissue sarcoma and ovarian cancer
    • Carter NJ, Keam SJ. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs. 2010;70:355-376.
    • (2010) Drugs. , vol.70 , pp. 355-376
    • Carter, N.J.1    Keam, S.J.2
  • 6
    • 33748035692 scopus 로고    scopus 로고
    • Cross-talk between nucleotide excision and homologous recombination dna repair pathways in the mechanism of action of antitumor trabectedin
    • Herrero AB, Martín-Castellanos C, Marco E, et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006;66:8155-8162.
    • (2006) Cancer Res. , vol.66 , pp. 8155-8162
    • Herrero, A.B.1    Martín-Castellanos, C.2    Marco, E.3
  • 7
    • 0031848159 scopus 로고    scopus 로고
    • Ecteinascidin-743 a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts
    • Valoti G, Nicoletti MI, Pellegrino A, et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res. 1998;4:1977-1983.
    • (1998) Clin Cancer Res. , vol.4 , pp. 1977-1983
    • Valoti, G.1    Nicoletti, M.I.2    Pellegrino, A.3
  • 8
    • 0032693607 scopus 로고    scopus 로고
    • High antitumour activity of et743 against human tumour xenografts from melanoma, nonysmall-cell lung and ovarian cancer
    • Hendriks HR, Fiebig HH, Giavazzi R, et al. High antitumour activity of ET743 against human tumour xenografts from melanoma, nonYsmall-cell lung and ovarian cancer. Ann Oncol. 1999;10:1233-1240.
    • (1999) Ann Oncol. , vol.10 , pp. 1233-1240
    • Hendriks, H.R.1    Fiebig, H.H.2    Giavazzi, R.3
  • 9
    • 0037341360 scopus 로고    scopus 로고
    • Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis
    • Morioka H, Weissbach L, Vogel T, et al. Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin Cancer Res. 2003;9: 1211-1217.
    • (2003) Clin Cancer Res. , vol.9 , pp. 1211-1217
    • Morioka, H.1    Weissbach, L.2    Vogel, T.3
  • 10
    • 0141731283 scopus 로고    scopus 로고
    • Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.
    • Donald S, Verschoyle RD, Greaves P, et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res. 2003;63:5902-5908.
    • (2003) Cancer Res. , vol.63 , pp. 5902-5908
    • Donald, S.1    Verschoyle, R.D.2    Greaves, P.3
  • 11
    • 0035281734 scopus 로고    scopus 로고
    • Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patientsvpreliminary evidence of activity
    • Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patientsVpreliminary evidence of activity. J Clin Oncol. 2001;19:1248-1255.
    • (2001) J Clin Oncol. , vol.19 , pp. 1248-1255
    • Delaloge, S.1    Yovine, A.2    Taamma, A.3
  • 12
    • 1542398698 scopus 로고    scopus 로고
    • Phase ii study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients
    • Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22:890-899.
    • (2004) J Clin Oncol. , vol.22 , pp. 890-899
    • Yovine, A.1    Riofrio, M.2    Blay, J.Y.3
  • 13
    • 72949084796 scopus 로고    scopus 로고
    • Trabectedin: An anticancer drug from the sea
    • Ganjoo KN, Patel SR. Trabectedin: an anticancer drug from the sea. Expert Opin Pharmacother. 2009;10: 2735-2743.
    • (2009) Expert Opin Pharmacother. , vol.10 , pp. 2735-2743
    • Ganjoo, K.N.1    Patel, S.R.2
  • 14
    • 37049038819 scopus 로고    scopus 로고
    • A phase ii study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
    • Krasner CN, McMeekin DS, Chan S, et al. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007;97:1618-1624.
    • (2007) Br J Cancer. , vol.97 , pp. 1618-1624
    • Krasner, C.N.1    McMeekin, D.S.2    Chan, S.3
  • 15
    • 20144377216 scopus 로고    scopus 로고
    • Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails
    • Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol. 2005;23:1867-1874.
    • (2005) J Clin Oncol. , vol.23 , pp. 1867-1874
    • Sessa, C.1    De Braud, F.2    Perotti, A.3
  • 16
    • 77955491837 scopus 로고    scopus 로고
    • Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
    • Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28:3107-3114.
    • (2010) J Clin Oncol. , vol.28 , pp. 3107-3114
    • Monk, B.J.1    Herzog, T.J.2    Kaye, S.B.3
  • 17
    • 84866736948 scopus 로고    scopus 로고
    • Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
    • Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012;48:2361-2368.
    • (2012) Eur J Cancer. , vol.48 , pp. 2361-2368
    • Monk, B.J.1    Herzog, T.J.2    Kaye, S.B.3
  • 18
    • 79960329488 scopus 로고    scopus 로고
    • The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary
    • Mabuchi S, Hisamatsu T, Kawase C, et al. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary. Clin Cancer Res. 2011;17:4462-4473.
    • (2011) Clin Cancer Res. , vol.17 , pp. 4462-4473
    • Mabuchi, S.1    Hisamatsu, T.2    Kawase, C.3
  • 19
    • 69949109923 scopus 로고    scopus 로고
    • Mtor is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary
    • Mabuchi S, Kawase C, Altomare DA, et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res. 2009;15:5404-5413.
    • (2009) Clin Cancer Res. , vol.15 , pp. 5404-5413
    • Mabuchi, S.1    Kawase, C.2    Altomare, D.A.3
  • 20
    • 0034047312 scopus 로고    scopus 로고
    • Phase i dose-finding and pharmacokinetic trial of irinotecan hydrochloride (cpt-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy
    • Pitot HC, Goldberg RM, Reid JM, et al. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res. 2000;6:2236-2244.
    • (2000) Clin Cancer Res. , vol.6 , pp. 2236-2244
    • Pitot, H.C.1    Goldberg, R.M.2    Reid, J.M.3
  • 21
    • 59449088659 scopus 로고    scopus 로고
    • Evaluation of lapatinib and topotecan combination therapy: Tissue culture, murine xenograft, and phase i clinical trial data
    • Molina JR, Kaufmann SH, Reid JM, et al. Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res. 2008;14:7900-7908.
    • (2008) Clin Cancer Res. , vol.14 , pp. 7900-7908
    • Molina, J.R.1    Kaufmann, S.H.2    Reid, J.M.3
  • 22
    • 53049092830 scopus 로고    scopus 로고
    • A phase i study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
    • von Mehren M, Schilder RJ, Cheng JD, et al. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol. 2008;19:1802-1809.
    • (2008) Ann Oncol. , vol.19 , pp. 1802-1809
    • Von Mehren, M.1    Schilder, R.J.2    Cheng, J.D.3
  • 23
    • 0142089888 scopus 로고    scopus 로고
    • The combination of yondelis and cisplatin is synergistic against human tumor xenografts
    • D'Incalci M, Colombo T, Ubezio P, et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer. 2003;39:1920-1926.
    • (2003) Eur J Cancer. , vol.39 , pp. 1920-1926
    • D'Incalci, M.1    Colombo, T.2    Ubezio, P.3
  • 24
    • 0042878545 scopus 로고    scopus 로고
    • Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.
    • Meco D, Colombo T, Ubezio P, et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol. 2003;52:131-138.
    • (2003) Cancer Chemother Pharmacol. , vol.52 , pp. 131-138
    • Meco, D.1    Colombo, T.2    Ubezio, P.3
  • 25
    • 0034786774 scopus 로고    scopus 로고
    • Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (et-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells
    • Takahashi N, Li WW, Banerjee D, et al. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res. 2001;7:3251-3257.
    • (2001) Clin Cancer Res. , vol.7 , pp. 3251-3257
    • Takahashi, N.1    Li, W.W.2    Banerjee, D.3
  • 26
    • 24044480041 scopus 로고    scopus 로고
    • Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft
    • Riccardi A, Meco D, Ubezio P, et al. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. Anticancer Drugs. 2005;16:811-815.
    • (2005) Anticancer Drugs. , vol.16 , pp. 811-815
    • Riccardi, A.1    Meco, D.2    Ubezio, P.3
  • 27
    • 0036279836 scopus 로고    scopus 로고
    • Pharmacology of topoisomerase i inhibitors irinotecan (cpt-11) and topotecan
    • Mathijssen RH, Loos WJ, Verweij J, et al. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets. 2002;2:103-123.
    • (2002) Curr Cancer Drug Targets. , vol.2 , pp. 103-123
    • Mathijssen, R.H.1    Loos, W.J.2    Verweij, J.3
  • 28
    • 18544367200 scopus 로고    scopus 로고
    • Inhibition of phosphorylation of bad and raf-1 by akt sensitizes human ovarian cancer cells to paclitaxel
    • Mabuchi S, Ohmichi M, Kimura A, et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem. 2002;277:33490-33500.
    • (2002) J Biol Chem. , vol.277 , pp. 33490-33500
    • Mabuchi, S.1    Ohmichi, M.2    Kimura, A.3
  • 29
    • 33748994272 scopus 로고    scopus 로고
    • Role for drug transporters beyond tumor resistance: Hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity
    • Kroetz DL. Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. J Clin Oncol. 2006;24:4225-4227.
    • (2006) J Clin Oncol. , vol.24 , pp. 4225-4227
    • Kroetz, D.L.1
  • 30
    • 0032739648 scopus 로고    scopus 로고
    • Reversal of mdr1-Associated resistance to topotecan by pak-200s, a new dihydropyridine analogue, in human cancer cell lines
    • Vanhoefer U, Müller MR, Hilger RA, et al. Reversal of MDR1-Associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines. Br J Cancer. 1999;81:1304-1310.
    • (1999) Br J Cancer. , vol.81 , pp. 1304-1310
    • Vanhoefer, U.1    Müller, M.R.2    Hilger, R.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.